BiotechTube
Home/Pipeline/PPR Editor for DM1

PPR Editor for DM1

Myotonic Dystrophy Type 1

PreclinicalActive

Key Facts

Indication
Myotonic Dystrophy Type 1
Phase
Preclinical
Status
Active
Company
EditForce

About EditForce

A biotech company developing programmable RNA-editing therapies using a proprietary PPR protein platform, initially targeting rare genetic diseases.

View full company profile

Therapeutic Areas

Rare DiseaseNeurological

Other Myotonic Dystrophy Type 1 Drugs

DrugCompanyPhase
JUV-161Juvena TherapeuticsPhase 1
DM1 TherapyKinea BioResearch
ENTR-701Entrada TherapeuticsPhase 1